RBC Capital raised the firm’s price target on Outset Medical (OM) to $14 from $12 and keeps a Sector Perform rating on the shares. The company’s Q1 Tablo consoles grew 23% q/q – first growth in six quarters) -while recurring revenue grew 20% y/y, and its commercial transformation is now behind with initiatives yielding results, the analyst tells investors in a research note. Outset’s FY25 guide looks conservative, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical Reports Strong Q1 Growth and Improved Margins
- Outset Medical’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Outset Medical reports Q1 EPS ($3.24)
- Outset Medical backs FY25 revenue view $115M-$125M, consensus $120.26M
- Positive Outlook for Outset Medical: Buy Rating and $15 Price Target Amid Share Adjustments and Market Trends